Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79(17):1757–1780

Article  PubMed  Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726

Article  CAS  PubMed  Google Scholar 

Liang B, Zhao Y-X, Zhang X-X, Liao H-L, Gu N (2020) Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovasc Diabetol 19(1):55

Article  PubMed  PubMed Central  Google Scholar 

Liang B, Li R, Bai J-Y, Gu N (2021) Bioimpedance vector analysis for heart failure: should we put it on the agenda? Front Cardiovasc Med 8:744243

Article  CAS  PubMed  PubMed Central  Google Scholar 

Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP et al (2018) Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 391(10120):572–580

Article  PubMed  PubMed Central  Google Scholar 

Savarese G, Lund LH (2017) Global public health burden of heart failure. Card Fail Rev 3(1):7–11

Article  PubMed  PubMed Central  Google Scholar 

Khera R, Kondamudi N, Zhong L, Vaduganathan M, Parker J, Das SR et al (2020) Temporal trends in heart failure incidence among medicare beneficiaries across risk factor strata, 2011 to 2016. JAMA Netw Open 3(10):e2022190

Article  PubMed  PubMed Central  Google Scholar 

Meyer S, Brouwers FP, Voors AA, Hillege HL, de Boer RA, Gansevoort RT et al (2015) Sex differences in new-onset heart failure. Clin Res Cardiol 104(4):342–350

Article  PubMed  Google Scholar 

Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ et al (2013) Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J. 34(19):1424–1431

Article  CAS  PubMed  Google Scholar 

Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS et al (2022) Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation 145(8):e153–e639

Article  PubMed  Google Scholar 

van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoeven H, Rutten FH (2014) Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 16(7):772–777

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34

Article  PubMed  Google Scholar 

Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J et al (2015) Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol 65(25):2739–2746

Article  PubMed  PubMed Central  Google Scholar 

Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P et al (2019) Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J 40(22):1756–1763

Article  PubMed  Google Scholar 

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229–4361

Article  PubMed  Google Scholar 

Tromp J, Boerman LM, Sama IE, Maass S, Maduro JH, Hummel YM et al (2020) Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls. Eur J Heart Fail 22(7):1239–1246

Article  CAS  PubMed  Google Scholar 

Boekel NB, Duane FK, Jacobse JN, Hauptmann M, Schaapveld M, Sonke GS et al (2020) Heart failure after treatment for breast cancer. Eur J Heart Fail 22(2):366–374

Article  CAS  PubMed  Google Scholar 

Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A et al (2018) Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail 20(5):879–887

Article  PubMed  Google Scholar 

Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A et al (2020) Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 22(11):1945–1960

Article  PubMed  Google Scholar 

Keramida K, Farmakis D, Bingcang J, Sulemane S, Sutherland S, Bingcang RA et al (2019) Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients. Eur J Heart Fail 21(4):529–535

Article  CAS  PubMed  Google Scholar 

Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J et al (2020) Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail 22(9):1504–1524

Article  PubMed  Google Scholar 

Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J et al (2021) Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol 77(4):392–401

Article  CAS  PubMed  Google Scholar 

Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T et al (2020) Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail 22(2):350–361

Article  CAS  PubMed  Google Scholar 

Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S et al (2020) Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail 22(11):1966–1983

Article  CAS  PubMed  Google Scholar 

Banke A, Fosbøl EL, Møller JE, Gislason GH, Andersen M, Bernsdorf M et al (2018) Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. Eur J Heart Fail 20(10):1447–1453

Article  CAS  PubMed  Google Scholar 

Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E et al (2019) Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy. Breast Cancer Res Treat 176(2):261–270

Article  PubMed  Google Scholar 

O’Brien P, Matheson K, Jeyakumar A, Anderson K, Younis T (2019) The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 174(2):357–363

Article  CAS  PubMed  Google Scholar 

Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M (2018) Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. JACC Cardiovasc Imaging 11(8):1084–1093

Article  PubMed  PubMed Central  Google Scholar 

Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23):2474–2481

Article  CAS  PubMed  Google Scholar 

Kourek C, Touloupaki M, Rempakos A, Loritis K, Tsougkos E, Paraskevaidis I et al (2022) Cardioprotective strategies from cardiotoxicity in cancer patients: a comprehensive review. J Cardiovasc Dev Dis 9(8)

Janbabai G, Nabati M, Faghihinia M, Azizi S, Borhani S, Yazdani J (2017) Effect of enalapril on preventing anthracycline-induced cardiomyopathy. Cardiovasc Toxicol 17(2):130–139

Article  CAS  PubMed  Google Scholar 

Nabati M, Janbabai G, Baghyari S, Esmaili K, Yazdani J (2017) Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol 69(5):279–285

Article  CAS  PubMed  Google Scholar 

Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM et al (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 61(23):2355–2362

Article  CAS  PubMed  Google Scholar 

Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW et al (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37(21):1671–1680

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang S, Zhao Q, Yang ZG, Diao KY, He Y, Shi K et al (2019) Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol. Heart Fail Rev 24(3):325–333

Article  CAS  PubMed  Google Scholar 

Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha V et al (2019) Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC CardioOncol 1(1):54–65